CNTX — what changed in the latest 10-Q

Text added vs the prior filing · source: 10-Q · 2026-08-05

• We had also been developing CT-95, a Mesothelin (“MSLN”) x CD3 TCE. However, on August 5, 2026, we announced a portfolio prioritization and capital allocation strategy, pursuant to which we discontinued internal development of CT-95 and will focus our development efforts on CTIM-76 and CT-202.

• CTIM-76 is a CLDN6 x CD3 TCE that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. CLDN6 is a tight junction membrane protein target expressed in multiple solid tumors and absent from or expressed at low levels in healthy adult tissues. On May 2, 2024, we announ…

• CTIM-76 is advancing into every-three-week (“Q3W”) dosing in patients with platinum-resistant ovarian cancer (“PROC”). In the second half of 2026, we plan to evaluate CTIM-76 using a Q3W dosing regimen in less heavily pretreated PROC patients to further characterize its clinical profile in a larger …

• CT-202 is a Nectin-4 x CD3 TCE that targets Nectin-4, a cell surface protein that is highly and frequently overexpressed in a variety of solid tumors, including bladder, colorectal, lung and breast. Nectin-4 is a clinically validated target for cancer therapy using a traditional antibody-drug conjug…

• CT-95 is an MSLN x CD3 TCE that is intended to redirect T-cell-mediated lysis toward malignant cells expressing MSLN. The first patient in our CT-95 Phase 1 trial was dosed in April 2025. We expect to wind down the CT-95 Phase 1 trial promptly in connection with our decision to discontinue internal …

Text removed vs the prior filing · source: 10-Q · 2026-05-06

• CTIM-76 is a CLDN6 x CD3 TCE that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. CLDN6 is a tight junction membrane protein target expressed in multiple solid tumors and absent from or expressed at low levels in healthy adult tissues. IND-enabling studies on C…

• CT-95 is an MSLN x CD3 TCE that is intended to redirect T-cell-mediated lysis toward malignant cells expressing MSLN. MSLN is a membrane protein overexpressed in approximately 30% of cancers. We dosed the first patient in our CT-95 Phase 1 trial in April 2025. We expect to share Phase 1a interim dat…

• CT-202 is a Nectin-4 x CD3 TCE that targets Nectin-4, a cell surface protein that is highly and frequently overexpressed in a variety of solid tumors, including bladder, colorectal, lung and breast. Nectin-4 is a clinically validated target for cancer therapy using a traditional antibody-drug conjug…

• We were incorporated in April 2015 under the laws of the State of Delaware. Since inception, we have devoted substantially all of our resources to developing product and technology rights, conducting research and development, organizing and staffing our company, business planning and raising capital…

• In April 2021, we entered into a collaboration and licensing agreement with Integral Molecular, Inc. (“Integral”) (the “Integral License Agreement”) for the development of a CLDN6 bsAb for cancer therapy. On February 29, 2024, we further amended (the "Second Amendment") the Research Collaboration an…

Text added vs the prior filing · source: 10-Q · 2026-08-05

• On May 1, 2026, the Provider paid the Mootness Fee in full pursuant to the Letter Agreement. The Action has since been closed.

Text removed vs the prior filing · source: 10-Q · 2026-05-06

• On May 1, 2026, the Provider paid the Mootness Fee in full pursuant to the Letter Agreement. The Action will be closed after the Court is informed a quorum was achieved at the Company’s 2026 annual meeting of stockholders, which is scheduled to be held on June 24, 2026.

Text added vs the prior filing · source: 10-Q · 2026-08-05

• We may not be able to regain or maintain compliance with the continued listing standards of Nasdaq.

• Our common stock is listed on the Nasdaq Capital Market, and we are therefore subject to its continued listing requirements, including requirements with respect to the market value of publicly-held shares, market value of listed shares, minimum bid price per share, and minimum stockholders’ equity, …

• For example, on July 29, 2026, we received a letter from Nasdaq notifying us that, because the closing bid price for our common stock had closed below $1.00 per share for 30 consecutive business days, we no longer complied with the minimum bid price requirement for continued listing on the Nasdaq Ca…

• (the “Minimum Bid Price Requirement”). Nasdaq’s notice has no immediate effect on the listing of our common stock, and, in accordance with Nasdaq Listing Rule 5810(c)(3)(A), we have until January 25, 2027 to regain compliance with the Minimum Bid Price Requirement by maintaining a closing bid price …

• We actively monitor our stock price, and, as appropriate, will consider implementing available options to regain or maintain compliance with the Minimum Bid Price Requirement. There can be no assurance, however, that we will be able to regain or maintain compliance with the Minimum Bid Price Require…

Text added vs the prior filing · source: 10-Q · 2026-08-05

• •an amendment (the “Lehr Amendment”) to that certain Amended and Restated Employment Agreement by and between us and Martin Lehr, our Chief Executive Officer, dated October 22, 2021 (the “Lehr Employment Agreement”);

• •an amendment (the “Minai-Azary Amendment”) to that certain Employment Agreement by and between us and Jennifer Minai-Azary, our Chief Financial Officer, dated November 1, 2021 (the “Minai-Azary Employment Agreement”); and

• •an amendment (the “Levit Amendment”) to that certain Employment Agreement by and between us and Alex Levit, our Chief Legal Officer and Corporate Secretary, dated October 22, 2021 (the “Levit Employment Agreement”).

• The Lehr Amendment, the Minai-Azary Amendment and the Levit Amendment are collectively referred to as the “Employment Agreement Amendments.” The Lehr Employment Agreement, the Minai-Azary Employment Agreement and the Levit Employment Agreement are collectively referred to as the “Employment Agreemen…

• The Employment Agreement Amendments revised the executives’ change in control severance protections by extending the protection period to include the three months preceding a Change in Control (as defined in the Employment Agreements). As a result, an executive officer who is terminated by us withou…